Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Enoximone→

Enoximone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
77671-31-9
Molecular formula
C12H12N2O2S
Molecular weight
248.3 g/mol
Drug class
Selective phosphodiesterase-3 (PDE3) inhibitorinodilator
Mechanism of action
Inhibits cardiac and vascular phosphodiesterase-3, increasing intracellular cyclic AMP. This produces positive inotropic activity and vasodilation, reducing cardiac loading conditions.
Indications / reported uses
  • Short-term intravenous inotropic support in severe congestive heart failure in settings and jurisdictions where enoximone is available; not a routine long-term heart-failure therapy

Sources: NLM MeSH — Enoximone · Westmead Anaesthetic Manual — Enoximone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Enoximone Environmental Risk Assessment (ERA) (the Enoximone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.